Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.
Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.
Replacement of potassium in patients with hypokalemia,Prevention of hypokalemia in patients who would be at risk from developing this condition,Source of calories and fluid in parenteral nutrition when potassium supplementation is required
Cardiac resuscitation (e.g., asystole, pulseless electrical activity) due to hyperkalemia, hypocalcemia, or calcium channel blocker overdose,Severe hypocalcemia,Treatment of hypermagnesemia,Treatment of calcium channel blocker overdose,Cardiopulmonary bypass,Intraoperative floppy iris syndrome (off-label)
Intravenous infusion at a rate not exceeding 10 m Eq/hour (0.75 m Eq/kg/hour). Typical dose: 20-40 m Eq potassium chloride in 1 liter D5W administered over 8-12 hours.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.
Potassium has no true elimination half-life as it is an endogenous electrolyte; redistribution half-life is approximately 1–1.5 hours for exogenous loads, reflecting cellular uptake and renal excretion. In anephric patients, half-life extends to 12–24 hours due to reliance on gastrointestinal and dialysis excretion.
2-4 hours in patients with normal renal function; prolonged in renal impairment.
Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and subsequent pathways to carbon dioxide and water, yielding energy.
Calcium chloride dissociates to release calcium ions which are primarily regulated by the kidney; no significant hepatic metabolism.
Renal: >90% of potassium excreted by kidneys, with distal tubular secretion and reabsorption. Fecal: ~10% eliminated via gastrointestinal tract. Biliary: negligible.
Primarily renal (80-90% as ionized calcium); minor fecal elimination (<10%).
~10% bound to plasma proteins (albumin). Unbound fraction is physiologically active.
Approximately 45-50% bound primarily to albumin.
Total body potassium Vd ~0.5 L/kg (approximates lean body mass). For intravenously administered potassium: initial Vd approximates extracellular fluid (0.2 L/kg) with redistribution into cells over 15–30 minutes. Clinical meaning: Low Vd indicates rapid equilibration; loading doses must account for intracellular shift to avoid hyperkalemia.
0.5-0.6 L/kg; primarily distributed in extracellular fluid.
Intravenous: 100%. Oral: ~90% (absorbed in small intestine). No other routes relevant.
Not applicable; administered only intravenously. Oral calcium salts have variable bioavailability (25-40%).
GFR >50 m L/min: No adjustment. GFR 30-50 m L/min: Reduce dose by 25-50%. GFR 10-30 m L/min: Reduce dose by 50-75%. GFR <10 m L/min: Avoid use or use with extreme caution; consider alternative.
GFR 30-60 m L/min: Use with caution; monitor serum calcium and phosphate levels. GFR <30 m L/min: Avoid use or use only if benefit outweighs risk; reduce dose by 50% and monitor serum calcium and phosphate closely.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50% due to risk of hyperkalemia. Child-Pugh C: Avoid use; alternative therapy recommended.
No dose adjustment recommended for Child-Pugh Class A or B. Child-Pugh Class C: Use with caution; monitor serum calcium and cardiac function due to potential for accumulation of calcium and effects on myocardial contractility.
Neonates and infants: 0.5-1 m Eq/kg/dose IV, not to exceed 0.5 m Eq/kg/hour. Children: 1-3 m Eq/kg/day IV, maximum infusion rate 0.5-1 m Eq/kg/hour; maximum concentration 40 m Eq/L.
IV: 0.2 m L/kg (20 mg/kg) of 10% solution, administered slowly at a rate not exceeding 0.5-1 m L/min. Dose may be repeated if needed. Maximum single dose: 1 g (10 m L).
Start at lower end of dosing range (e.g., 10-20 m Eq per liter) and titrate slowly. Monitor renal function and serum potassium frequently. Maximum infusion rate: 5-10 m Eq/hour.
No specific dose adjustment, but consider reduced renal function common in elderly; use lowest effective dose and monitor serum calcium, phosphate, and cardiac status. Infusion rate should be slow (0.5-1 m L/min) to avoid adverse effects.
Potassium chloride injections are for intravenous use only. Rapid infusion may cause hyperkalemia and cardiac arrest. Concentrated potassium chloride solutions (>=2 m Eq/m L) must be diluted before use. Do not administer undiluted.
Do not administer by intracardiac injection due to risk of myocardial rupture and cardiac arrest.
Monitor serum potassium levels frequently to avoid hyperkalemia,Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Do not administer if solution is discolored or contains particulate matter,Check for compatibility with other medications in the same line
Extravasation can cause tissue necrosis; administer slowly to avoid hypercalcemia; use with caution in digitalis toxicity as hypercalcemia potentiates digoxin toxicity; monitor serum calcium levels; avoid in patients with renal failure unless severe hypocalcemia exists.
Hyperkalemia,Severe renal impairment with oliguria or anuria,Conditions that cause potassium retention (e.g., Addison's disease, systemic acidosis),Hypersensitivity to potassium chloride or dextrose
Hypercalcemia, ventricular fibrillation during cardiac arrest, concurrent digitalis therapy (relative), patients with known hypersensitivity to calcium salts.
Avoid excessive consumption of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados) and salt substitutes containing potassium chloride. Limit high-sodium foods as they may affect fluid and electrolyte balance.
Avoid calcium-fortified foods and dairy products if serum calcium is elevated. High doses of vitamin D can increase calcium absorption, leading to hypercalcemia. Caffeine and alcohol may increase urinary calcium excretion, potentially reducing efficacy. Oxalate-rich foods (spinach, rhubarb) and phytate-rich foods (whole grains) bind calcium and may reduce absorption, but this is less relevant with IV administration.
Potassium chloride and dextrose are not teratogenic. There is no evidence of fetal harm from potassium chloride or dextrose at standard doses. Trimester-specific risks are not applicable.
No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly needed; high doses may cause hypercalcemia in fetus (e.g., hypotonia, poor feeding). Intravenous administration near term may suppress fetal parathyroid function.
Potassium chloride and dextrose are endogenous substances normally present in breast milk. No safety concerns at standard doses. M/P ratio not established; not clinically relevant as both are normal milk constituents.
Calcium is excreted in breast milk but in normal physiological amounts. M/P ratio not established; supplemental calcium likely safe but high IV doses may increase milk calcium concentration. Monitor infant for hypercalcemia with prolonged high-dose maternal therapy.
No specific dose adjustment required for pregnancy; however, monitor for fluid overload and electrolyte imbalances due to increased plasma volume and GFR in pregnancy; adjust rate based on serum potassium and glucose.
No specific dose adjustment required; pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may necessitate higher doses to achieve desired serum calcium levels, but titrate to effect and serum calcium monitoring. Avoid bolus administration during labor; use slow IV infusion.
Administer via central line if concentration exceeds 0.1% (20 m Eq/L) to avoid phlebitis. Do not exceed infusion rate of 10 m Eq/hour. Contraindicated in severe renal impairment (Cr Cl <30 m L/min), hyperkalemia, or Addison's disease. Monitor ECG for peaked T waves and serum potassium levels. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics.
Calcium chloride provides approximately 3 times more elemental calcium per m L than calcium gluconate. Due to its high osmolality (approx. 2000 m Osm/L), it is a severe vesicant; central line administration is strongly preferred to prevent tissue necrosis if extravasation occurs. For peripheral IV, use a large bore vein with good blood flow and avoid hand/wrist veins. In cardiac arrest (e.g., hyperkalemia, calcium channel blocker overdose), give 10 m L of 10% solution (1 g) IV push; may repeat every 10 minutes if needed. Monitor serum calcium, magnesium, and phosphate levels; correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia. Contraindicated in digitalis toxicity (can precipitate fatal arrhythmias). Not for IM or SC use.
Report any signs of hyperkalemia such as muscle weakness, palpitations, or tingling sensations.,Avoid potassium-containing salt substitutes or supplements unless approved by your doctor.,This solution contains dextrose; if you have diabetes, monitor blood glucose closely.,Inform your healthcare provider about all medications, especially heart or blood pressure medicines.,Do not stop or change the infusion rate on your own.
Report any burning, pain, or swelling at the IV site immediately.,This medication increases calcium levels; do not take additional calcium supplements or antacids without doctor approval.,Calcium can interfere with the absorption of certain antibiotics (tetracyclines, fluoroquinolones) and thyroid medications; separate doses by at least 2-4 hours.,Avoid excessive intake of vitamin D or calcium-rich foods unless directed by your doctor.,Seek emergency care if you experience chest pain, irregular heartbeat, or muscle cramps.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/hour (0.75 m Eq/kg/hour). Typical dose: 20-40 m Eq potassium chloride in 1 liter D5W administered over 8-12 hours.. The standard adult dose of CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic. There is no evidence of fetal harm from potassium chloride or dextrose at standard doses. Trimester-specific risks are not appl. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly ne. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.